Svend Freytag PhD

Svend O Freytag, PhD

medical group

Specialties: Research

About Me

Languages

English

Gender

Male

Biography

Dr. Freytag received his doctorate in biochemistry from Case Western Reserve University’s School of Medicine in 1981. Dr. Freytag completed his fellowship in the Pediatric Department of Baylor College of Medicine in Houston, TX, working with genetics. When his fellowship was complete, Dr. Freytag moved on to the University of Michigan’s Medical School where we worked as an Assistant Professor in the Department of Biological Chemistry.

In 1989 Dr. Freytag began working as a Senior Staff Scientist in the Molecular Biology Research Program for Henry Ford Health System in Detroit, MI. Dr. Freytag currently is Division Head of Research for Henry Ford’s Radiation Oncology Department. Dr. Freytag is a member of various professional societies including: Phi Kappa Phi Honorary, American Association for the Advancement of Science, American Association for Cancer Research, and American Association for Gene Therapy.

Awards, Honors and Publications
Honors and Awards:

Named Wendell W. Anderson Chair in Cancer - Henry Ford Health System, Detroit, MI, 2001 to present
Winner of The Creators Award - Crain's Detroit Business, 2000
NIH Postdoctoral Fellowship, Department of Pediatrics, Section of Genetics - Baylor College of Medicine, Houston, TX, 1982-1984
Cellular and Molecular Biology Traineeship - Department of Biochemistry, Case Western Reserve University School of Medicine. Cleveland, OH, 1977-1981
Graduated Summa cum laude - Department of Biochemistry, Purdue University, 1977

Presentations:

Gordon Research Conference on Nucleotides and Nucleosides, Newport, RI. Title of Talk: Clinical Studies of Replication-Competent Adenovirus-Mediated Suicide Gene Therapy With Conformal Radiotherapy for Cancer. 2005.
ASTRO/Radiation Research Meeting. Denver, CO. Title of Talk: Clinical Studies of Replication-Competent Adenovirus-Mediated Suicide Gene Therapy With Conformal Radiotherapy for Cancer. 2005.
Third International Conference of Translational Research and Pre-Clinical Strategies in Radiation Oncology. Lugano, Switzerland. Title of Talk: Clinical Studies of Replication-Competent Adenovirus-Mediated Suicide Gene Therapy With Conformal Radiotherapy for Cancer. 2006.

Publications:

Barton, K.N., Stricker, H., Brown, S.L., Lu, M., Pegg, J., Zhang, Y., Karvelis, K.C., Siddiqui, F., Kim, JH, Freytag, S.O., Movsas, B.  Phase 1 study of non-invasive imaging of adenovirus-mediated gene expression in the human prostate.  Mol Ther., In press, 2008.
Freytag, S.O., Barton, K., Zhang, Y., Paielli, D., Tyson, D., Nall, C., Brown, S., Narra, V., Lu, M., Ajlouni, M., Movsas, B., and Kim, JH.  Replication-competent adenovirus-mediated suicide gene therapy with radiation in a preclinical model of pancreatic cancer.  Mol Ther., 15: 1600-1606, 2007.
Freytag, S.O., Stricker, H., Movsas, B., and Kim, J-H.  Prostate cancer gene therapy clinical trials (review).  Mol Ther., 15: 1042-1052, 2007.
Freytag, S.O., Movsas, B., Aref, I., Stricker, H., Peabody, J., Pegg, J., Zhang, Y., Barton, K., Brown, S., Lu, M., Savera, A., and Kim, JH.  Phase I trial of replication-competent adenovirus-mediated suicide gene therapy with IMRT for prostate cancer.  Mol Ther., 15: 1016-1023, 2007.
Freytag, S.O., Stricker, H., Peabody, J., Pegg, J., Paielli, D., Movsas, B., Barton, K., Brown, S., Lu, M., and Kim, JH.  Five-year follow-up of trial of replication-competent adenovirus-mediated suicide gene therapy for treatment of prostate cancer.  Mol Ther., 15: 636-642, 2007.
Boucher, P.D., Im, M.M., Freytag, S.O. and Shewach, D.S.  A Novel Mechanism of Synergistic Cytotoxicity with 5-FC and GCV in Double Suicide Gene Therapy.  Cancer Res., 66: 3230-3237, 2006.
Barton, K., Paielli, D., Zhang, Y., Koul, S., Brown, S., Lu, M., Seely, J., Kim, J.H., and Freytag, S.O.  Second-generation replication-competent oncolytic adenovirus armed with improved suicide genes and the ADP gene demonstrate greater efficacy without increased toxicity.  Mol. Ther., 13: 347-356, 2006.
Freytag, S.O., Kim, J.H., Brown, S.L., Barton, K., Lu, M., and Chung, M.  Gene therapy strategies to enhance the effectiveness of cancer radiotherapy.  Cur. Opin. Mol. Ther., 6: 513-524, 2004.
Freytag, S.O., Stricker, H., Pegg, J., Paielli, D., Pradhan, D., Peabody, J., DePeralta-Venturina, M., Xia, X., Brown, S., Lu, M., and Kim, J.H.  Phase I study of replication-competent adenovirus-mediated double suicide gene therapy in combination with conventional dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer.  Cancer Res., 63: 7497-7506, 2003.
Freytag, S.O., Khil, M., Stricker, H., Peabody, J., Menon, M., DePeralta-Venturina, M., Nafziger, D., Pegg, J., Paielli, D., Brown, S., Barton, K., Lu, M., Aguilar-Cordova, E., and Kim, J.H.  Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer.  Cancer Res., 62: 4968-4976, 2002.
Adelmant, G., J.D. Gilbert, and S.O. Freytag.  Human TLS-CHOP oncoprotein prevents adipocyte differentiation by directly interfering with C/EBP? function.  J. Biol. Chem., 273: 15574-15581, 1998.
Freytag, S.O., and Geddes, T.J.  Reciprocal regulation of adipogenesis by Myc and C/EBP*.  Science, 256: 379-382, 1992.

Clinical Studies:

"Suicide Gene Therapy: A Phase I Study of E1B-Attenuated Replication Competent Adenovirus Vector-Mediated Intratumoral Administration of the E. coli Cytosine Deaminase/HSV-1 Thymidine Kinase Fusion Gene in Conjunction with Two Prodrugs, 5-Fluorocytosine and Ganciclovir for Patients with Local Recurrence of Prostate Cancer After Radiation Therapy". PI, Jae Ho Kim, M.D., Ph.D., Co-PI, Svend O. Freytag, Ph.D. BB-IND 8436. RAC protocol 9906-321. Completed.
"Phase I Study of Combined Suicide Gene Therapy and Radiation Therapy for Locally Advanced Carcinoma of the Prostate". PI, Jae Ho Kim, M.D., Ph.D., Co-PI, Svend O. Freytag, Ph.D. BB-IND 9852. RAC protocol 0104-464. Completed.
"Phase I Study of Replication-Competent Adenovirus-Mediated Double Suicide Gene Therapy in Combination With Conventional Dose Conformal Radiation Therapy For the Treatment of Intermediate- to High-Risk Prostate Cancer". PI, Jae Ho Kim, M.D., Ph.D., Co-PI, Svend O. Freytag, Ph.D. BB-IND 11253. RAC protocol 0307-590. Completed.
"Phase I Study Combining Suicide Gene Therapy with Conformal Radiotherapy for the Treatment of Human Cancer Using an Oncolytic Adenovirus That Can Be Imaged Non-Invasively In Vivo." PI, Benjamin Movsas, M.D., Co-PIs, Svend O. Freytag, Ph.D., Stephen L. Brown, Ph.D. and Kenneth N. Barton, Ph.D. BB-IND 12786. RAC protocol 0501-690. Completed.
"Phase I Study Combining Replication-Competent Adenovirus-Mediated Suicide Gene Therapy With Neoadjuvant Chemoradiotherapy in the Treatment of Potentially Resectable Pancreatic Cancer". PI, Munther Ajlouni, M.D., Co-PI, Svend O. Freytag, Ph.D. BB-IND 11253. RAC protocol 0601-754. Opened to enrollment November 2006.
"A RANDOMIZED, CONTROLLED TRIAL OF REPLICATION-COMPETENT ADENOVIRUS-MEDIATED SUICIDE GENE THERAPY IN COMBINATION WITH IMRT VERSUS IMRT ALONE FOR THE TREATMENT OF NEWLY-DIAGNOSED INTERMEDIATE-RISK PROSTATE CANCER". PI, Benjamin Movsas, M.D., Ph.D., Co-PI, Svend O. Freytag, Ph.D. BB-IND 11253. RAC protocol 0704-842. Opened to enrollment January 2008.
"A RANDOMIZED, CONTROLLED TRIAL OF REPLICATION-COMPETENT ADENOVIRUS-MEDIATED SUICIDE GENE THERAPY FOLLOWED BY ANDROGEN SUPPRESSION THERAPY (AST) AND DOCETAXEL/PREDNISONE (DOC/P) AT PROGRESSION VERSUS DOC/P AT PROGRESSION FOR THE TREATMENT OF LOCALLY RECURRENT PROSTATE CANCER". PI, Hans Stricker, M.D., Co-PI, Svend O. Freytag, Ph.D. BB-IND 8436. Pending.

Locations

2799 W Grand Blvd
Radiation Oncology - M-226
Detroit, MI 48202

Hospital Privileges

  • Henry Ford Hospital